31.12.2012 Views

official journal of the patent office - Controller General of Patents ...

official journal of the patent office - Controller General of Patents ...

official journal of the patent office - Controller General of Patents ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

(12) PATENT APPLICATION PUBLICATION (21) Application No.150/CHE/2005 A<br />

(19) INDIA<br />

(22) Date <strong>of</strong> filing <strong>of</strong> Application :23/02/2005 (43) Publication Date : 16/03/2007<br />

(54) Title <strong>of</strong> <strong>the</strong> invention : A NOVEL CRYSTALLINE FORM OF GEFITINIB AND A PROCESS FOR ITS<br />

PREPARATION<br />

(51) International classification :C07D<br />

239/94<br />

(31) Priority Document No :NA<br />

(32) Priority Date :NA<br />

(33) Name <strong>of</strong> priority country :NA<br />

(86) International Application No :NA<br />

Filing Date<br />

:NA<br />

(87) International Publication No : NA<br />

(61) Patent <strong>of</strong> Addition to Application :NA<br />

Number<br />

Filing Date<br />

:NA<br />

(62) Divisional to to Application Number :NA<br />

Filing Date<br />

:NA<br />

(71)Name <strong>of</strong> Applicant :<br />

1)NATCO PHARMA LIMITED<br />

Address <strong>of</strong> Applicant :NATCO HOUSE, ROAD<br />

NO.2, BANJARA HILLS, HYDERABAD-500 033<br />

Andhra Pradesh India<br />

(72)Name <strong>of</strong> Inventor :<br />

1)JYOTHI PRASAD RAMANADHAM<br />

2)VENKAIAH CHOWDARY NANNAPANENI<br />

No <strong>of</strong> Pages : 10 No <strong>of</strong> Claims : 5<br />

(57) Abstract :<br />

The present invention relates to a novel crystalline fonn <strong>of</strong> Gefitinib and a process for its<br />

Preparation <strong>the</strong>re<strong>of</strong>. Gefitinib is 4-(31-chloro-41-fluoro anilino)- 7-methoxy-6- (3-morpholino<br />

propoxy) quinazoline and has <strong>the</strong> structural formula-I The present invention is to provide a stable<br />

novel crystalline fonn <strong>of</strong> Gefitinib designated by us as Fonm-6, and a process for <strong>the</strong> preparation <strong>of</strong><br />

<strong>the</strong> same. Gefitinib is useful in <strong>the</strong> treatment <strong>of</strong> a variety <strong>of</strong> solid tumors, especially non-small cell<br />

lung cancer and hematological malignancies.<br />

The Patent Office Journal 16/03/2007 5455

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!